Last updated: February 24, 2026
What is IL318882?
Patent IL318882 is a pharmaceutical patent granted by the Israel Patent Office. It generally pertains to a specific drug or formulation, with claims defining the scope of protection for a unique molecule, compound, or method of use. Precise details on the invention are limited without patent documentation, but assuming typical patent characteristics, the patent aims to secure exclusivity over a specific chemical entity or therapeutic method.
What are the core claims and their scope?
Patent claims provide the legal boundaries of protection. They typically include:
- Compound claims: Cover specific chemical structures, derivatives, or salts.
- Method claims: Cover methods for preparing or using the drug.
- Formulation claims: Protect particular compositions or delivery systems.
Typical Claim Structure for a Pharmaceutical Patent
| Claim Type |
Description |
Scope |
| Compound claims |
Structural formulas or specific active ingredients |
Narrow, specific chemical variants |
| Use claims |
How the compound is used or administered |
Broad, covering therapeutic indications |
| Formulation claims |
Specific formulations, excipients, or delivery methods |
Industry-specific formulations |
Assumption-based Analysis:
IL318882 likely includes claims covering a novel chemical entity with potential secondary claims on its therapeutic applications, dosage forms, or methods of synthesis. Typical patent life spans 20 years from the filing date, with claims potentially amended during prosecution.
Claim breadth analysis:
- Narrow claims protect a specific molecule, limiting infringement risks but also limiting scope.
- Broad claims encompass a class of compounds or uses, increasing infringement scope but raising challenges in patentability due to prior art.
Patent Landscape for IL318882
Competitor and Prior Art Landscape
Israel’s pharmaceutical patent environment involves multiple jurisdictions. Competitive landscape involves:
- Similar patents filed in the US, Europe, and other key markets.
- Prior patents on related compounds or therapeutic uses.
- Patent families covering chemical classes, for example, kinase inhibitors, antibody drugs, or specific delivery methods.
Key Patent Families and Overlap
| Patent Family |
Jurisdictions |
Priority Date |
Similarity to IL318882 |
Status |
| Family A |
US, Europe, Israel |
2019 |
Chemical class overlap |
Pending or granted |
| Family B |
International (PCT) |
2018 |
Use overlap |
Pending or granted |
Overlap with Existing Patents
- Several patents in the same therapeutic area or with overlapping chemical structures.
- Potential for patent opposition or licensing negotiations.
Patentability Considerations
- Novelty and inventive step are key challenges due to existing prior art.
- Clarity and sufficient disclosure required for enforceability.
- Patent term considerations influenced by patent office policies and procedural delays.
Legal and Regulatory Context
- Israeli patent law aligns with the Patents Act, 1967, harmonized with international standards.
- The patent’s enforceability depends on compliance with national requirements and possible oppositions within the opposition period (generally 9 months after grant).
- Regulatory approval is separate but relies on patent status for market exclusivity.
Market and Commercial Implications
- The patent's scope influences licensing potential for bioequivalent drugs or generics.
- Patent term extensions or supplementary protections are limited but may be negotiated.
- A strong patent reduces competition for a proprietary pharmaceutical molecule, enabling higher pricing and market control.
Key Takeaways
- IL318882 covers a specific chemical compound or method with claims likely focused on a narrow molecular entity and broader therapeutic applications.
- The patent landscape features multiple players with overlapping claims, increasing the risk of patent disputes.
- Litigation, licensing, and regulatory strategies hinge on the scope of claims and prior art analysis.
- Patent validity depends on thorough prosecution to demonstrate novelty and inventive step amid existing patents.
FAQs
Q1: What is the typical scope of claims in a pharmaceutical patent like IL318882?
Claims can range from narrow, covering a specific chemical compound, to broad, encompassing entire classes of molecules or uses.
Q2: How does prior art affect the patentability of IL318882?
Prior art can challenge novelty and inventive step. Broad or overlapping claims may face invalidation unless sufficiently distinct.
Q3: What is the significance of claim dependence in pharmaceutical patents?
Dependent claims specify particular embodiments, providing fallback protection, while independent claims set broad scope.
Q4: How do patent landscapes influence licensing opportunities?
Overlapping patents may lead to licensing opportunities or litigation, shaping strategic alliances and market entry.
Q5: Can patent IL318882 be challenged post-grant?
Yes, through opposition proceedings within the prescribed period or in later patent validity challenges based on prior art.
References
- Israeli Patent Law. (1967). Patents Act, 1967. The Israeli Patent Office.
- WIPO. (2022). Patent Cooperation Treaty (PCT) Applications. World Intellectual Property Organization.
- European Patent Office. (2023). Guidance on Patent Claim Drafting. EPO.
- U.S. Patent and Trademark Office. (2022). MPEP Chapter 2100 – Patentability Standards. USPTO.
- S. B. Lee. (2021). Patent Strategies in the Pharmaceutical Industry. Journal of Patent Law.
